National Biologics Facility (NBF)
Brisbane, Queensland, Australia
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: National Biologics Facility (NBF)
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Brisbane, Queensland, Australia
- Modalities
- Mammalian Cell Culture, Recombinant Proteins, Monoclonal Antibody, Bispecifics, Antibody Fragments/Nanobodies, ADC (precursor), Vaccines, E. coli, Pichia yeast, Insect Cell Culture
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About National Biologics Facility (NBF)
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMammalian Cell Culture, Recombinant Proteins, Monoclonal Antibody, Bispecifics, Antibody Fragments/Nanobodies, ADC (precursor), Vaccines, E. coli, Pichia yeast, Insect Cell Culture
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (10 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (10 modalities)
Frequently Asked Questions About National Biologics Facility (NBF)
What is National Biologics Facility (NBF)'s CDMO Signal Score?
National Biologics Facility (NBF) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating National Biologics Facility (NBF) for a manufacturing program?
Use the free AI matchmaker to compare National Biologics Facility (NBF) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
CSIRO National Vaccine and Therapeutics Laboratory
Clayton, Victoria, Australia
Mammalian Cell Culture, Recombinant Proteins, Vaccines, Biologics (mammalian & insect)
BioCina
Adelaide, Australia
Biologics (Microbial), Plasmid DNA, mRNA, LNP, Sterile Fill-Finish, Recombinant Proteins, Vaccines, Biosimilars, High Potency/Oncology Injectables, Blow-Fill-Seal
Abzena
San Diego, CA; Bristol, PA; Cambridge, UK
Signal Score: 64.0
ADC, AOC, RDC, PDC, DAC, Fusion Proteins, Bispecifics, bsAbs, Multispecifics, msAbs, Bioconjugates, Biologics, mAb, Monoclonal Antibody, Antibodies, Cytokines, HPAPI, Bioconjugation
Cytovance Biologics
Oklahoma City, OK
Signal Score: 61.5
Microbial Fermentation, Biologics, Recombinant Proteins, Mammalian Cell Culture, Plasmid DNA
53Biologics
Boecillo (Valladolid), Spain
Biologics, Recombinant Proteins, Plasmid DNA, mRNA, Enzymes, Vaccines, Antibody Fragments